Synonyms: BMS 345825 | BMS 354825 | BMS 35482513 | Sprycel®
dasatinib is an approved drug (FDA & EMA (2006))
Compound class:
Synthetic organic
Comment: Dasatinib is a Type-1 kinase inhibitor and was first approved by the FDA in 2006.
A combination of dasatinib and quercetin has been investigated in animal models for senolytic activity [9,14,17]. Senolytic agents are intended to reduce the abundance of senescent cells as a mechanism to treat age-related diseases, reduce frailty and extend healthy lifespan [2,6-7,16]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: dasatinib |
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA & EMA (2006)) |
WHO Essential Medicine | WHO Essential Medicines List (EML) (23rd List, 2023). Access PDF version. Click to view more information about the WHO Model Lists of Essential Medicines. |
IUPAC Name |
N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide |
International Nonproprietary Names | |
INN number | INN |
8712 | dasatinib |
Synonyms |
BMS 345825 | BMS 354825 | BMS 35482513 | Sprycel® |
Database Links | |
Specialist databases | |
Reactome Drug | R-ALL-9669723 |
Reactome Reaction | R-HSA-9669900, R-HSA-9674430, R-HSA-9669854, R-HSA-9669855, R-HSA-9674095 |
Other databases | |
CAS Registry No. | 302962-49-8 |
ChEMBL Ligand | CHEMBL1421 |
DrugBank Ligand | DB01254 |
DrugCentral Ligand | 785 |
GtoPdb PubChem SID | 178102305 |
PubChem CID | 3062316 |
RCSB PDB Ligand | 1N1 |
Search Google for chemical match using the InChIKey | ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | ZBNZXTGUTAYRHI |
Search PubMed clinical trials | dasatinib |
Search PubMed titles | dasatinib |
Search PubMed titles/abstracts | dasatinib |
SynPHARM | 78746 (in complex with ABL proto-oncogene 1, non-receptor tyrosine kinase) |
UniChem Compound Search for chemical match using the InChIKey | ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | ZBNZXTGUTAYRHI-UHFFFAOYSA-N |
Wikipedia | Dasatinib |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Dasatinib (links to external site)
Cat. No. 6793 |